International Stem Cell (ISCO) Notes Payables (2018 - 2026)
International Stem Cell (ISCO) posted quarterly Notes Payables of $3.3 million for Q4 2025, down 1.62% year-over-year from $3.4 million in Q4 2024, and up 1.06% quarter-over-quarter from $3.3 million in Q3 2025.
International Stem Cell (ISCO) Notes Payables (2018 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Notes Payables for 7 consecutive years, with $3.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Notes Payables fell 1.62% year-over-year to $3.3 million; the TTM figure through Dec 2025 stood at $3.3 million (down 1.62% YoY), while the FY2025 annual figure was $3.3 million, down 1.62% from the prior year.
- Notes Payables advanced to $3.3 million in Q4 2025 per ISCO's latest filing, from $3.3 million in the prior quarter.
- Across five years, Notes Payables topped out at $3.5 million in Q2 2024 and bottomed at $2.9 million in Q1 2021.
- Historically, Notes Payables has averaged $3.3 million across 5 years, with a median of $3.3 million in 2022.
- Annual changes were most pronounced in 2021 — Notes Payables climbed 19.08% — and 2025, when it decreased 7.18%.
- International Stem Cell's Notes Payables stood at $2.9 million in 2021, then gained by 12.98% to $3.3 million in 2022, then climbed by 3.97% to $3.5 million in 2023, then retreated by 1.79% to $3.4 million in 2024, then retreated by 1.62% to $3.3 million in 2025.
- Business Quant data shows ISCO's Notes Payables at $3.3 million in Q4 2025, $3.3 million in Q3 2025, and $3.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.26 Mn |
| Dec 31, 2025 | 3.34 Mn |
| Sep 30, 2025 | 3.31 Mn |
| Jun 30, 2025 | 3.27 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Dec 31, 2024 | 3.40 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 3.52 Mn |
| Mar 31, 2024 | 3.49 Mn |
| Dec 31, 2023 | 3.46 Mn |
| Sep 30, 2023 | 3.42 Mn |
| Jun 30, 2023 | 3.39 Mn |
| Mar 31, 2023 | 3.36 Mn |
| Dec 31, 2022 | 3.33 Mn |
| Sep 30, 2022 | 3.29 Mn |
| Jun 30, 2022 | 3.26 Mn |
| Mar 31, 2022 | 3.23 Mn |
| Dec 31, 2021 | 2.94 Mn |
| Sep 30, 2021 | 2.91 Mn |
| Jun 30, 2021 | 2.88 Mn |